Unveiling the oncogenic role of CLDN11-secreting fibroblasts in gastric cancer peritoneal metastasis through single-cell sequencing and experimental approaches

Liu, Kanghui; Wang, Yanjuan; Shao, Wenwen; Tang, Chong; Zhao, Siguo; Xu, Jiafeng; Xu, Peng; Cheng, Quan; Huang, Shansong; Ji, Peicheng; Qiu, Shengkui

doi:10.1016/j.intimp.2024.111647

Cited by 4 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of an immunological tumor center, which includes tumor-reactive chemokine ligand 13 (CXCL13) T cells, epithelial interferon-stimulated gene programs, and early immune remodelling characterized by enhanced infiltration of CD8+ T cells, is responsible for the clinical response to first-line chemoimmunotherapy for advanced GC [31]. Claudin 11 (CLDN11) and atypical chemokine receptor 3 (ACKR3), traditionally called CXCR7-positive fibroblasts, are crucial for the management of GC with peritoneal metastases [32]. A retrospective cohort study evaluated the role of neoadjuvant chemoimmunotherapy by camrelizumab + nab-paclitaxel + S−1 vs. neoadjuvant chemotherapy alone by nab-paclitaxel in 128 patients with GC.…”

Section: Treatmentmentioning

confidence: 99%

Prognosis and Treatment of Gastric Cancer: A 2024 Update

Burz,

Pop,

Silaghi

et al. 2024

Cancers

View full text Add to dashboard Cite

Due to the high death rate associated with gastric cancer, a great deal of research has been conducted on this disease. The goal of this paper was to start a trimestral review of 2024 for the year that had just started. The scientific literature from 1 January 2024 was chosen with consideration of the the guidelines of the European Society of Medical Oncology (ESMO), which are updated with new findings but not systematically reviewed annually. We used the search term “gastric cancer” to find the most current publications in the PubMed database related to the prognosis and treatment of gastric cancer. As previously said, the only articles that satisfied the inclusion criteria were those from 2024. Articles with case reports were eliminated since they had nothing to do with our research. The treatment of gastric cancer is the focus of the majority of articles from 2024. The primary research axes include surgery and immunonutrition, immunotherapy and Helicobacter pylori, and therapeutic targets. Patients with GC may experience less psychological, social, and financial hardship if the recently identified markers discovered in circulation are better assessed and validated. This could be achieved by either including the markers in an artificial intelligence-based diagnostic score or by using them in conjunction with traditional diagnostic methods. Due to the rising death rate associated with GC, funding for research into diagnosis, prognosis, therapy, and therapeutic targets is essential.

show abstract

Section: Treatmentmentioning

confidence: 99%

Prognosis and Treatment of Gastric Cancer: A 2024 Update

Burz,

Pop,

Silaghi

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Cancer-associated fibroblasts (CAFs) produce a range of cytokines, chemokines, and growth factors that both directly sustain cancer cells and modify the immune cell milieu (10). These factors not only serve as a survival cue for cancer cells but also manipulate the immune landscape by dampening immune effector cell function and attracting immunosuppressive cells, facilitating cancer cell evasion of immune surveillance (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

BNIP3 + cancer-associated fibroblasts and their associated genes are accelerators of pancreatic cancer

Shao,

Zhang,

Zhao

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Pancreatic cancer is one of the most malignant gastrointestinal tumors. Due to the difficulty of early diagnosis and limited treatment, the prognosis of pancreatic cancer patients is very poor. Pancreatic cancer is characterized by high interstitial fibrosis, in which activation of cancer-associated fibroblasts (CAFs) plays a key role. CAFs is the most abundant cell in the pancreatic tumor microenvironment, with a high degree of plasticity, and participates in various processes of tumor development through crosstalk with tumor cells and other cells in the microenvironment. Elucidate the heterogeneity of CAFs and its mechanism of action, which helps find a new effective treatment for pancreatic cancer. Methods We used single-cell RNA sequencing (scRNA-seq) transcriptomics to analyze fibroblasts from pancreatic cancer patient specimens. This approach was able to identify key subpopulations of fibroblasts and elucidate their contribution to pancreatic cancer progression. Subsequently, we established a prediction model for pancreatic cancer using Cox regression and the LASSO algorithm and conducted cell experiments to verify it. Results Our study identified a BNIP3 + tumor-associated fibroblast and used this cell-associated gene to construct a prognostic model of pancreatic cancer, a feature that effectively divided PDAC patients into high-risk and low-risk groups and outperformed traditional clinicopathological features in predicting survival outcomes in pancreatic cancer patients. In vitro co-culture experiments showed that BNIP3 + fibroblasts could have more effects on pancreatic cancer cells. Conclusion We screened C1 BNIP3 + pancreatic cancer-associated fibroblasts, which advanced our knowledge and understanding of CAFs heterogeneity. The prognostic model we constructed can effectively predict the prognosis and treatment response of pancreatic cancer.

show abstract